Shenzhen Salubris Pharmaceuticals (002294) Q3 2024 earnings summary

Executive summary

• Revenue for the first three quarters reached ¥3.00 billion, up 22.18% year-over-year, with net profit attributable to shareholders at ¥509.71 million, up 6.37% year-over-year.

• Innovative products and brand recognition drove growth, with new product launches and increased acceptance among doctors and patients.

• R&D projects advanced steadily, with several Phase III and II clinical trials progressing and new products entering the market.

Financial highlights

• Operating income for Q3 was ¥958.43 million, a 24.15% increase compared to the same quarter last year.

• Net profit attributable to shareholders for Q3 was ¥165.62 million, up 17.01% year-over-year.

• Net profit excluding non-recurring items for Q3 was ¥163.60 million, up 30.87% year-over-year.

• Operating cash flow for the first three quarters was ¥853.91 million, up 59.63% year-over-year.

• Total assets at quarter-end were ¥10.23 billion, up 8.90% from the previous year-end.

Outlook and guidance

• Innovative product revenue and profit contribution are expected to continue rising, with stable income from generic drugs.

• Hospital access and clinical application of new products are progressing well, outperforming similar competitors.

• Negotiations for inclusion of additional innovative products in the national insurance directory are ongoing.